Buprenorphine Liquid Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Buprenorphine Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   Innishannon
   County Cork - Ireland
   Telephone : 353 214329300
   Telefax : 908-735-1496
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Not a hazardous substance or mixture.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Not a hazardous substance or mixture.

2.3 Other hazards
   None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

| Components |
|-----------------|-----------------|-----------------|-----------------|
| Chemical name   | CAS-No. EC-No. Index-No. Registration number | Classification | Concentration (% w/w) |
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Buprenorphine Liquid Formulation

Version 1.8  Revision Date: 23.03.2020  SDS Number: 749663-00009  Date of last issue: 13.09.2019
Date of first issue: 08.06.2016

<table>
<thead>
<tr>
<th>Substance/Composition</th>
<th>CAS Number</th>
<th>Acute Tox. 3; H301</th>
<th>Repr. 1A; H360Df</th>
<th>STOT SE 3; H336</th>
<th>Aquatic Chronic 2; H411</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine Hydrochloride</td>
<td>53152-21-9 258-396-8</td>
<td>&gt;= 0.025 - &lt; 0.1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures
   Protection of first-aiders: No special precautions are necessary for first aid responders.
   If inhaled: If inhaled, remove to fresh air.
   Get medical attention if symptoms occur.
   In case of skin contact: Wash with water and soap as a precaution.
   Get medical attention if symptoms occur.
   In case of eye contact: Flush eyes with water as a precaution.
   Get medical attention if irritation develops and persists.
   If swallowed: If swallowed, DO NOT induce vomiting.
   Get medical attention if symptoms occur.
   Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed
   None known.

4.3 Indication of any immediate medical attention and special treatment needed
   Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media
   Suitable extinguishing media: Water spray
   Alcohol-resistant foam
   Carbon dioxide (CO2)
   Dry chemical
   Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture
   Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.
   Hazardous combustion products: Carbon oxides
5.3 Advice for firefighters

Special protective equipment for firefighters: Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Handle in accordance with good industrial hygiene and safety
practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers:
Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage:
Do not store with the following product types:
Strong oxidizing agents

7.3 Specific end use(s)
Specific use(s):
No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine Hydrochloride</td>
<td>53152-21-9</td>
<td>TWA</td>
<td>0.2 µg/m³ (OEB 5)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>2 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
No open handling permitted.
Totally enclosed processes and materials transport systems are required.
Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment
Eye protection:
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection

Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection

: No personal respiratory protective equipment normally required.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : liquid

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available
Buprenorphine Liquid Formulation

SECTION 1: Identification

1.1 Product identifier

Buprenorphine Liquid Formulation

1.2 Supplier identifier

MSD

1.3 Other identification numbers

SIRN: 749663-00009

SECTION 2: Hazard(s) identification

2.1 Physical and Chemical properties

Partition coefficient: n-octanol/water
Auto-ignition temperature
Decomposition temperature
Viscosity
Explosive properties
Oxidizing properties

2.2 Other hazardous properties

Partition coefficient: n-octanol/water
Auto-ignition temperature: No data available
Decomposition temperature: No data available
Viscosity: No data available
Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids): No data available
Particle size: Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid: None known.

10.5 Incompatible materials

Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of exposure: Inhalation, Skin contact, Ingestion, Eye contact

Acute toxicity

Not classified based on available information.
Components:

Buprenorphine Hydrochloride:
Acute oral toxicity: LD50 (Mouse): 261 mg/kg
LD50 (Rat): 600 mg/kg
Acute inhalation toxicity: Remarks: No data available
Acute dermal toxicity: Remarks: No data available
Acute toxicity (other routes of administration): LD50 (Rat): 31 mg/kg
Application Route: Intravenous
LD50 (Mouse): 24 mg/kg
Application Route: Intravenous

Skin corrosion/irritation
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Remarks: No data available

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Remarks: No data available

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Remarks: No data available

Germ cell mutagenicity
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Buprenorphine Liquid Formulation

Result: equivocal

Test Type: Chromosomal aberration
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: positive

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Species : Rat
Application Route : Oral
Exposure time : 27 Months
LOAEL : 56 mg/kg body weight
Result : positive
Target Organs : Testes
Remarks : The significance of these findings for humans is not certain.

Species : Mouse
Application Route : Oral
Exposure time : 86 weeks
NOAEL : 100 mg/kg body weight
Result : negative

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

Reproductive toxicity
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 80 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 5 mg/kg body weight
Result: No effects on fertility
### Test Types and Results

**Test Type**: Fertility  
**Species**: Rabbit  
**Application Route**: Oral  
**Fertility**: LOAEL: 1 mg/kg body weight  
**Result**: Preimplantation loss

**Test Type**: Fertility  
**Species**: Rabbit  
**Application Route**: Intravenous  
**Fertility**: LOAEL: 0.2 mg/kg body weight  
**Result**: Postimplantation loss.

### Effects on Foetal Development

<table>
<thead>
<tr>
<th>Species</th>
<th>Application Route</th>
<th>Developmental Toxicity</th>
<th>LOAEL</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Subcutaneous</td>
<td>LOAEL: 5 mg/kg body weight</td>
<td>5 mg/kg body weight</td>
<td>Embryo-foetal toxicity, No teratogenic effects, Skeletal malformations</td>
</tr>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>NOAEL: 160 mg/kg body weight</td>
<td>No effects on foetal development</td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>Subcutaneous</td>
<td>LOAEL: 0.1 mg/kg body weight</td>
<td>0.1 mg/kg body weight</td>
<td>Effects on newborn</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Oral</td>
<td>LOAEL: 1 mg/kg body weight</td>
<td>1 mg/kg body weight</td>
<td>Embryo-foetal toxicity, Skeletal malformations</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Intramuscular</td>
<td>LOAEL: 5 mg/kg body weight</td>
<td>5 mg/kg body weight</td>
<td>Embryo-foetal toxicity, Skeletal malformations</td>
</tr>
</tbody>
</table>

### Reproductive Toxicity - Assessment

May damage the unborn child. Suspected of damaging fertility.

### STOT - Single Exposure

Not classified based on available information.

### Components:

**Buprenorphine Hydrochloride**

Assessment: May cause drowsiness or dizziness.
STOT - repeated exposure
Not classified based on available information.

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Buprenorphine Hydrochloride:

Inhalation:
- Target Organs: Central nervous system
- Symptoms: Drowsiness, sedation, Headache, Nausea, Vomiting, Dizziness, Vertigo, Sweating, constipation, insomnia, Pain, respiratory depression, constriction of pupils, decrease in heart rate, Lowered blood pressure
- Remarks: May cause neonatal withdrawal

SECTION 12: Ecological information

12.1 Toxicity

Components:

Buprenorphine Hydrochloride:

Toxicity to algae/aquatic plants:
- EC50 (Pseudokirchneriella subcapitata (green algae)): 6.25 mg/l
- Exposure time: 72 h
- Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 0.319 mg/l
- Exposure time: 72 h
- Method: OECD Test Guideline 201

Toxicity to microorganisms:
- EC50: 588 mg/l
- Exposure time: 3 h
- Test Type: Respiration inhibition
- Method: OECD Test Guideline 209
- NOEC: 135 mg/l
- Exposure time: 3 h
- Test Type: Respiration inhibition
- Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity):
- NOEC: 0.137 mg/l
- Exposure time: 28 d
- Species: Pimephales promelas (fathead minnow)
- Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC: 0.883 mg/l
- Exposure time: 21 d
- Species: Daphnia magna (Water flea)
- Method: OECD Test Guideline 211
Buprenorphine Liquid Formulation

12.2 Persistence and degradability

Components:

Buprenorphine Hydrochloride:
Biodegradability: Result: Not readily biodegradable.

12.3 Bioaccumulative potential

Components:

Buprenorphine Hydrochloride:
Bioaccumulation:
Species: Oncorhynchus mykiss (rainbow trout)
Bioconcentration factor (BCF): 0.4
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 3.11

12.4 Mobility in soil

Components:

Buprenorphine Hydrochloride:
Distribution among environmental compartments: log Koc: 4.11

12.5 Results of PBT and vPvB assessment

Not relevant

12.6 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product:
Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging:
Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.
SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECS : not determined
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Buprenorphine Liquid Formulation

Version 1.8  Revision Date: 23.03.2020  SDS Number: 749663-00009  Date of last issue: 13.09.2019
Date of first issue: 08.06.2016

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-statements

H301: Toxic if swallowed.
H336: May cause drowsiness or dizziness.
H360Df: May damage the unborn child. Suspected of damaging fertility.
H411: Toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox.: Acute toxicity
Aquatic Chronic: Long-term (chronic) aquatic hazard
Repr.: Reproductive toxicity
STOT SE: Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; ICSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Sub-
# Buprenorphine Liquid Formulation

**Version**: 1.8  
**Revision Date**: 23.03.2020  
**SDS Number**: 749663-00009  
**Date of last issue**: 13.09.2019  
**Date of first issue**: 08.06.2016

stances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

## Further information

<table>
<thead>
<tr>
<th>Sources of key data used to compile the Safety Data Sheet</th>
</tr>
</thead>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN